T cell receptor specific for Ornithine decarboxylase 1 (ODC1)-derived neoantigen peptide–MHC complex (ODC1-neoantigen TCR)

The T cell receptor (TCR) specific for the Ornithine decarboxylase 1 (ODC1)-derived neoantigen peptide–MHC complex is a specialized immune receptor engineered to recognize mutated forms of the ODC1 enzyme. Ornithine decarboxylase 1 is a critical rate-limiting enzyme in the polyamine biosynthesis pathway, and its dysregulation is a hallmark of various malignancies, including neuroblastoma and colorectal cancer (Hogarty et al., 2008, PubMed). Mutations in the ODC1 gene can result in the production of neoantigens—novel peptides that are processed and presented by the Major Histocompatibility Complex (MHC) on the surface of tumor cells (Rosenberg et al., 2015, Science). This TCR is designed to bind with high affinity and specificity to these ODC1-derived neoantigen-MHC complexes, bypassing the limitations of the natural immune repertoire which may be tolerant to self-antigens. Upon binding, the TCR initiates a signaling cascade through the CD3 complex, leading to the activation, proliferation, and cytotoxic activity of the T cell against the tumor (Nature Reviews Cancer, 2021). This approach is primarily utilized in adoptive cell transfer therapies, where a patient's T cells are genetically modified to express the ODC1-specific TCR to treat advanced solid tumors.

Other names

ODC1-specific TCRAnti-ODC1 neoantigen T-cell receptorODC1-pMHC-specific T-cell receptorODC1-targeted TCR

The TCR specifically binds to a neoantigenic peptide derived from mutated Ornithine decarboxylase 1 (ODC1) presented by MHC molecules, triggering T-cell activation via CD3 signaling and subsequent tumor cell lysis.